AUM Biosciences

AUM is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker.

AUM is aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology.

AUM Biosciences was founded in 2018 by Vishal Doshi and Harish Dave. The company is headquartered in Singapore, with offices in New York and Victoria, AU.

 

AUM holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR).

 

AUM utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets.

 

AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation.

 

AUM Biosciences is backed by Everlife, SPRIM Global investments (SGI), and others. The company completed a $27M Series A round on Oct 12, 2021. This brings AUM's total funding to $28.5M to date.

 

 

 

  • Year founded: 2018
  • Funding Info: $28.5M over 2 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Singapore
  • State: Central Region
  • Country: Singapore
Related businesses